The final rules of reverse CFIUS differ from the draft version; China changes its foreign investment rules to attract more long-term and high-quality investments; and Chinese data center company raises $1 billion from U.S. PE investors.
The world's largest drone manufacturer fights allegations by the U.S. Defense Department, Commerce Department, and House of Representatives; Chinese government invests in Chinese startups after U.S. venture capital and private equity funds leave China; and Chinese insurance regulator approves insurance firms set up by BNP Paribas and Prudential.
Geopolitical tensions, tightening foreign investment restrictions, and a poorly performing Chinese economy are some of the challenges facing private equity investors trying to exit their investments. Whilst the preferred exit method depends on the transaction itself, there are ways to minimize the general risks of exit methods
U.S. plans to restrict Chinese software in electric and internet-connected cars; China increases control over offshore capital flows; and Chinese firms plan to expand into the U.S. Midwest but have regulatory concerns.
Geoffrey Chan and Angela Liu of Skadden, Arps, Slate, Meagher & Flom in Hong Kong examine key structuring considerations for international companies planning to establish a corporate venture capital arm in China or elsewhere in Asia
The U.S. has added additional Chinese companies to its Entity List and Unverified List; China's State Council has taken steps to encourage foreign venture capital in the tech sector; and Chinese electrolyzer manufacturers are "Europeanizing" their products in anticipation of an EU crackdown.
The U.S. publishes details on "Reverse CFIUS;" Shein's London listing might face obstacles; and two of the top 10 VC deals globally involve China, with much of the funding coming from Chinese state-backed investors.
International investors find Chinese secondary PE market an alternative amid U.S.-China tensions; QuantumPharm is the first IPO under Hong Kong's new measure for pre-revenue specialist technology firms; and China releases new carbon measuring standards foreseeing new EU carbon tariffs.
Western companies are investing in Chinese biotech even amid continued geopolitical tension between China and the West and decreasing appetite for foreign investment in China; Two lithium battery part manufacturers, Capchem and Kedaliplan, plan to build factories in the U.S. to avoid hefty lithium battery tariffs; and Chinese pharma firm Asymchem to take over U.K. Pfizer plant.
Charles Wu of Clyde & Co describes the current regulatory state of China's investment market, for private equity investors, including the much anticipated recent clarity provided by key regulators as well as potential pitfalls to avoid
